Home/ Stocks/ IBRX

ImmunityBio, Inc. Common Stock

IBRX XNAS

$7.46 +0.15 (+2.05%) ▲ 15-min delayed

Open

$7.34

High

$7.51

Low

$7.26

Volume

792.9K

Market Cap

$7.67B

About ImmunityBio, Inc. Common Stock

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 691 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$44.21M	$-632,797,000	$-0.62
FY 2025	$113.29M	$-351,472,000	$-0.38
Q3 2025	$32.06M	$-67,274,000	$-0.07
Q2 2025	$26.43M	$-92,574,000	$-0.10

TickerDaily Coverage

Why Is ImmunityBio, Inc. Common Stock (IBRX) Stock Down 28.0% Today?

Market News David Brooks · Mar 24, 2026

ImmunityBio stock plummeted 28.0% on March 24, 2026, dropping from $9.40 to $6.885 despite recent...

View All Coverage →

Get IBRX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on ImmunityBio, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.